Oct. 13 (UPI) -- Pfizer and its German partner BioNTech announced on Thursday that their Omicron booster shots substantially increased antibody protection against the BA.5 subvariant of COVID-19 in preliminary tests.
"The early data suggest that our bivalent vaccine is anticipated to provide better protection against currently circulating variants than the original vaccine,"Pfizer CEO Albert Bourla said in a press statement.